Literature DB >> 11802908

The Edinburgh Postnatal Depression Scale: validation in a Norwegian community sample.

M Eberhard-Gran1, A Eskild, K Tambs, B Schei, S Opjordsmoen.   

Abstract

This study was undertaken to validate a Norwegian translation of the Edinburgh Postnatal Depression Scale (EPDS). The EPDS was validated against the DSM-IV criteria for major depression, derived from the PRIME-MD, in an interview study of 56 women selected from a community-based questionnaire study of 310 women 6 weeks postpartum. A score of > or =10 on the EPDS scale identified all women with major depression, giving a sensitivity of 100% (95% confidence interval; 72%-100%) and a specificity of 87% (95% confidence interval; 77%-95%). The EPDS scores were strongly correlated with the Montgomery-Asberg Depression Rating Scale in the subsample of women interviewed (n=56) and with the Hopkins Symptom Check List (SCL-25) scores in the questionnaire study (n=310). Our results with regard to the sensitivity and specificity estimates are comparable with prior validation studies; however, the confidence intervals around the estimates are wide. Nevertheless, this study confirms that the EPDS is a valid clinical screening instrument for detecting postpartum depression.

Entities:  

Mesh:

Year:  2001        PMID: 11802908     DOI: 10.1080/08039480151108525

Source DB:  PubMed          Journal:  Nord J Psychiatry        ISSN: 0803-9488            Impact factor:   2.202


  35 in total

1.  Self-reported short sleep duration and insomnia symptoms as predictors of post-pregnancy weight change: Results from a cohort study.

Authors:  Kamilla Rognmo; Børge Sivertsen; Malin Eberhard-Gran
Journal:  Womens Health (Lond)       Date:  2016-09-15

2.  Parenting Stress Plays a Mediating Role in the Prediction of Early Child Development from Both Parents' Perinatal Depressive Symptoms.

Authors:  Eivor Fredriksen; Tilmann von Soest; Lars Smith; Vibeke Moe
Journal:  J Abnorm Child Psychol       Date:  2019-01

3.  Assessing the quality of diagnostic studies using psychometric instruments: applying QUADAS.

Authors:  Rachel Mann; Catherine E Hewitt; Simon M Gilbody
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2008-10-04       Impact factor: 4.328

4.  An intervention to reduce postpartum depressive symptoms: a randomized controlled trial.

Authors:  Elizabeth A Howell; Susan Bodnar-Deren; Amy Balbierz; Holly Loudon; Pablo A Mora; Caron Zlotnick; Jason Wang; Howard Leventhal
Journal:  Arch Womens Ment Health       Date:  2013-09-10       Impact factor: 3.633

5.  The Impact of Perinatal Depression on Children's Social-Emotional Development: A Longitudinal Study.

Authors:  Carolin Junge; Susan Garthus-Niegel; Kari Slinning; Carolin Polte; Tone Breines Simonsen; Malin Eberhard-Gran
Journal:  Matern Child Health J       Date:  2017-03

6.  Reducing postpartum depressive symptoms among black and Latina mothers: a randomized controlled trial.

Authors:  Elizabeth A Howell; Amy Balbierz; Jason Wang; Michael Parides; Caron Zlotnick; Howard Leventhal
Journal:  Obstet Gynecol       Date:  2012-05       Impact factor: 7.661

7.  Somatic symptoms and diseases are more common in women exposed to violence.

Authors:  Malin Eberhard-Gran; Berit Schei; Anne Eskild
Journal:  J Gen Intern Med       Date:  2007-10-06       Impact factor: 5.128

8.  Sleep and depression in postpartum women: a population-based study.

Authors:  Signe Karen Dørheim; Gunnar Tschudi Bondevik; Malin Eberhard-Gran; Bjørn Bjorvatn
Journal:  Sleep       Date:  2009-07       Impact factor: 5.849

9.  Pregnant people's responses to the COVID-19 pandemic: a mixed-methods, descriptive study.

Authors:  Hamideh Bayrampour; Sukhpreet K Tamana; Amelie Boutin
Journal:  CMAJ Open       Date:  2022-02-22

10.  Measuring the risk factors for postpartum depression: development of the Japanese version of the Postpartum Depression Predictors Inventory-Revised (PDPI-R-J).

Authors:  Mari Ikeda; Kiyoko Kamibeppu
Journal:  BMC Pregnancy Childbirth       Date:  2013-05-14       Impact factor: 3.007

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.